Hingham, MA -- January 4, 2021 -- Applied Tissue Technologies (ATT), an advanced wound care company, announced the publication of a peer reviewed study in Plastic and Reconstructive Surgery Journal®, "Study Comparing Platform Wound Dressing (PWD® ), a Negative-Pressure Device without a Filler, with Three Conventional Negative-Pressure Wound Therapy Systems in the Treatment of Excisional and Incisional Wounds". The Study was selected as an editor's pick and is available without charge in full text online.
In general the devices showed similar efficacy with the PWD® being more effective in reducing open wound surface area and depth.
The preclinical GLP study compared the new, embossed PWD® (ATT, Hingham, MA) that does not use a wound filler material of gauze or foam to the three most common NPWT devices that do utilize foam or gauze; VAC ViaTM, (3M, St. Paul, MN), PrevenaTM (3M, St. Paul, MN), and PICOTM (Smith and Nephew, UK). The devices were compared in three different wound types and an independent observer was utilized to remove bias. The study was conducted as part of a United States Department of Defense grant.
"We're pleased to see that this simplified negative pressure system, the PWD, showed similar results as the common devices used today and that it reduced wound depth more rapidly," commented Elof Eriksson MD, PhD and Chief Medical Officer of ATT. Additionally Dr. Eriksson stated that, "We can now provide a negative pressure device, the PWD, that is transparent for wound monitoring and without the potential problems of foam and gauze."
The patented PWD is a transparent dressing with an integral adhesive base and a permanently embossed impermeable membrane that combines the traditional functions of the NPWT membrane and foam/gauze in currently marketed NPWT devices. In the PWD, no foam or gauze is needed. When the NPWT pump is switched on, the embossed membrane superstructure is redundant which allows it to be pulled into direct contact with all geometries of the wound. The space created between the embossments provides primary channels for air and fluid, while folds in the membrane create secondary channels that provide an even distribution of negative pressure across the wound.
ATT has completed the first of three ongoing clinical trials funded by the United States Department of Defense to evaluate the PWD and is in the process of publishing the results.
The PWD is a member ATT’s portfolio of advanced wound care products including, the Xpansion® MicroAutografting Kit and establishes a product line of advanced wound care technologies that can reestablish the skin barrier function, deliver topical therapeutics and close wounds with the gold standard of wound healing, an autologous split thickness skin graft.
Applied Tissue Technologies
Applied Tissue Technologies brings advancements in wound healing to patients. This includes research and development supported by the United States Department of Defense to help wounded warriors at the point of injury, instances of prolonged field care and delayed evacuation, and also continuing through advanced levels of military medical care. www.appliedtissue.com @npwtsimplified
The PWD is supported in part by the United States Defense Health Agency (Small Business Innovation Research), USAMRAA, and USAMRMC through contract numbers W81XWH-18-2-0002,
W81XWH-18-C-0143, W81XWH-19-2-0038 and W81XWH-16-0784. The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.